mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for MAP4K4
Gene summary
Basic gene Info.Gene symbolMAP4K4
Gene namemitogen-activated protein kinase kinase kinase kinase 4
SynonymsFLH21957|HEL-S-31|HGK|MEKKK4|NIK
CytomapUCSC genome browser: 2q11.2-q12
Type of geneprotein-coding
RefGenesNM_001242559.1,
NM_001242560.1,NM_004834.4,NM_145686.3,NM_145687.3,
DescriptionHPK/GCK-like kinase HGKMAPK/ERK kinase kinase kinase 4MEK kinase kinase 4Ste20 group protein kinase HGKepididymis secretory protein Li 31hepatocyte progenitor kinase-like/germinal center kinase-like kinasenck-interacting kinase
Modification date20141207
dbXrefs MIM : 604666
HGNC : HGNC
Ensembl : ENSG00000071054
HPRD : 05235
Vega : OTTHUMG00000155394
ProteinUniProt: O95819
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_MAP4K4
BioGPS: 9448
PathwayNCI Pathway Interaction Database: MAP4K4
KEGG: MAP4K4
REACTOME: MAP4K4
Pathway Commons: MAP4K4
ContextiHOP: MAP4K4
ligand binding site mutation search in PubMed: MAP4K4
UCL Cancer Institute: MAP4K4
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0006468protein phosphorylation9890973
GO:0035556intracellular signal transduction9890973
GO:0046328regulation of JNK cascade14966141


Top
Ligand binding site mutations for MAP4K4

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
I82,R80N81HCOAD1
S77Y76FGBM1
D153R152GSKCM1
V31V30ASTAD1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for MAP4K4
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
V31V30A-1.8207955
D153R152G-1.321913
I82N81H-0.94852495
R80N81H-0.94852495
S77Y76F-0.85392353
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for MAP4K4 from PDB

Top
Differential gene expression and gene-gene network for MAP4K4
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of MAP4K4 and the right PPI network was created from samples without mutations in the LBS of MAP4K4. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for MAP4K4
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for MAP4K4
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of MAP4K4 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
ANPAMP-PNP4u40AD153
MGMAGNESIUM(2+)4obpAS77 I82
MGMAGNESIUM(2+)4obqAS77 I82
MGMAGNESIUM(2+)4u45AS77 I82
MGMAGNESIUM(2+)4zk5AS77 I82
MGMAGNESIUM(2+)4u40AS77 I82
MGMAGNESIUM(2+)4u41AS77 I82
MGMAGNESIUM(2+)4u42BS77 I82
MGMAGNESIUM(2+)4u42AS77 R80 I82
2QV6-(3-CHLOROPHENYL)QUINAZOLIN-4-AMINE4oboAV31
2QU6-(2-FLUOROPYRIDIN-4-YL)PYRIDO[3,2-D]PYRIMIDIN-4-AMINE4obpAV31
3D8N-(PYRIDIN-3-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-AMINE4u43AV31
3D96-PHENYL-N-(PYRIDIN-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN- 4-AMINE4u44AV31
3DC6-(1H-PYRAZOL-4-YL)-N-(PYRIDIN-4-YL)PYRROLO[2,1-F][1,2, 4]TRIAZIN-4-AMINE4u45AV31
3XM3-HEXANOYL-4-HYDROXY-5-(4-HYDROXYPHENYL)PYRIDIN-2(1H)- ONE4rvtAV31
4P4GNE-4958-AMINO-N-[1-(CYCLOPROPYLCARBONYL)AZETIDIN-3-YL]-2-(3- FLUOROPHENYL)-1,7-NAPHTHYRIDINE-5-CARBOXAMIDE4zk5AV31
5DF4-{6-AMINO-5-[4-(METHYLSULFONYL)PHENYL]PYRIDIN-3- YL}PHENOL5di1AV31


Top
Conservation information for LBS of MAP4K4
Multiple alignments for O95819 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas